Femoropopliteal Artery Disease Clinical Trial
- Prospective, randomized, controlled, multi-center study - A total of 240 subjects with femoropopliteal artery disease will be included according to inclusion and exclusion criteria. - Patients will be randomized in a 1:1 manner into IVUS-guided or angiography-guided intervention group. - Second 1:1 randomization into dual antiplatelet therapy (aspirin + clopidogrel) or triple antiplatelet therapy (aspirin + clopidogrel + cilostazol) is optional - All patients will be treated with drug-coated balloons (In.PACT Admiral) for femoropopliteal lesions. - Bare metal self-expandable stents will be used in addition according to findings of IVUS or angiography such as severity of arterial dissection or residual stenosis. - Patients will be followed clinically for 1 year after the procedure. - Ankle-brachial index and Image study follow-up (Duplex US or CT angiography) will be performed at 1 year.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02145065 -
First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r)
|
N/A | |
Recruiting |
NCT05307263 -
Combination Therapy of Atherectomy Plus Drug-coated Balloon Versus Drug-coated Balloon for Complex Femoropopliteal Artery Disease
|
N/A | |
Recruiting |
NCT02701881 -
Comparison of the PrimAry Long Versus Short Coverage With Drug-Eluting Stents for Long FemoRopopliteal Artery DiseasE (PARADE II): Investigator-initiated Clinical Study
|
Phase 4 | |
Recruiting |
NCT02701816 -
Korean Multicenter Registry of INNOVA Stent for Femoropopliteal Artery Disease: (K-INNOVA Registry)
|